Investors should monitor upcoming clinical catalysts, particularly the topline Phase 3 data for firmonertinib in mid-2026, which could significantly impact valuation. The strong cash position provides runway through Q3 2027, reducing near-term dilution risk.
Price Chart
Executive Summary
ArriVent BioPharma reported its full-year 2025 financial results, highlighting clinical progress with its lead asset firmonertinib and advancement of its ADC pipeline. The company reported a net loss of $166.3 million and ended the year with $312.8 million in cash, sufficient to fund operations into Q3 2027. Key upcoming catalysts include topline Phase 3 data for firmonertinib in mid-2026.
Key Financial Metrics
Key Facts
- Net loss was $166.3 million for 2025, up from $80.5 million in 2024
- Cash and investments totaled $312.8 million as of December 31, 2025
- Cash runway expected to extend into Q3 2027
- Completed enrollment in the FURVENT Phase 3 trial for firmonertinib in EGFR exon 20 insertion NSCLC
- Dosed first patient in the ALPACCA Phase 3 trial for firmonertinib in PACC mutant NSCLC
- NMPA approval received in China for firmonertinib in second-line EGFR exon 20 insertion NSCLC
- ARR-217 ADC program advanced to Phase 1 with FDA IND clearance and first patient dosed in March 2026
Financial Impact
Increased R&D spending to $153.4 million in 2025 from $79.0 million in 2024, driven by clinical development and a one-time payment to Lepu Biopharma
Risk Factors
- Clinical trial results may not meet endpoints, particularly for the pivotal FURVENT and ALPACCA studies
- Increased R&D expenses could pressure cash runway if development timelines extend
- Regulatory approval is not guaranteed despite Breakthrough Therapy Designation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-024112 |
| Document: avbp-20260305x8k.htm | 0001104659-26-024112 |
| Document: 0001104659-26-024112-index-headers.html | 0001104659-26-024112 |
| Document: 0001104659-26-024112-index.html | 0001104659-26-024112 |
| Document: 0001104659-26-024112.txt | 0001104659-26-024112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $14.86 (−37.14%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $14.86 (−17.17%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $14.86 (−8.27%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $14.86 (−7.64%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $14.86 (+11.18%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $14.86 (+1.52%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $14.86 (+50.47%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $14.86 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers